{"id":540757,"date":"2021-04-27T20:26:01","date_gmt":"2021-04-27T20:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=540757"},"modified":"2021-04-27T20:26:01","modified_gmt":"2021-04-27T20:26:01","slug":"nonsmall-cell-lung-cancer-nsclc-pipeline-assessment-key-companies-and-emerging-drugs","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/nonsmall-cell-lung-cancer-nsclc-pipeline-assessment-key-companies-and-emerging-drugs_540757.html","title":{"rendered":"Non-Small Cell Lung Cancer (NSCLC) Pipeline Assessment, Key Companies, And Emerging Drugs"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Non-Small Cell Lung Cancer (NSCLC) Pipeline Assessment, Key Companies, And Emerging Drugs\" src=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" alt=\"Non-Small Cell Lung Cancer (NSCLC) Pipeline Assessment, Key Companies, And Emerging Drugs\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">&#8220;Non-Small Cell Lung Cancer (NSCLC) Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Non-Small Cell Lung Cancer (NSCLC) Market. <\/div>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">The <strong>Non-Small Cell Lung Cancer (NSCLC) Pipeline<\/strong><\/span><span data-mce-mark=\"1\"><strong> report<\/strong> embraces in-depth <\/span><span data-mce-mark=\"1\">commercial <\/span><span data-mce-mark=\"1\">and clinical assessment of the Non-Small Cell Lung Cancer (NSCLC) pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><span data-mce-mark=\"1\">The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, <\/span><strong><span data-mce-mark=\"1\">Non-Small Cell Lung Cancer (NSCLC) collaborations<\/span><\/strong><span data-mce-mark=\"1\">, mergers, acquisition, funding, designations, and other product-related details.<\/span><\/p>\n<p style=\"text-align: justify;\"><strong>Get FREE sample copy at<\/strong>&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/non-small-cell-lung-cancer-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Non-Small Cell Lung Cancer (NSCLC) Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/acb2d75d24d77348f2102b27e5d7ea50.jpg\" alt=\"Non-Small Cell Lung Cancer (NSCLC) Pipeline Analysis\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Non-Small Cell Lung Cancer (NSCLC) Therapies Covered in the report include:<\/strong><br \/>AMG 510<br \/>SAR408701<br \/>PADCEV<br \/>TAK-788<br \/>Avelumab<br \/>Veliparib<br \/>Romiplostim<br \/>Canakinumab<br \/>Braftovi+Mektovi<br \/>Sitravatinib (MGCD516)<br \/>INCMGA00012\/MGA012<br \/>TEPMETKO (tepotinib)<br \/><strong>And many more.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong><span data-mce-mark=\"1\">Non-Small Cell Lung Cancer (NSCLC) Pipeline Analysis<\/span><\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">The report provides insights into:&nbsp;<\/span><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The report provides detailed insights about companies that are developing therapies for the <\/span><strong><span data-mce-mark=\"1\">treatment of Non-Small Cell Lung Cancer (NSCLC) <\/span><\/strong><span data-mce-mark=\"1\">with aggregate therapies developed by each company for the same.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the <strong>Non-Small Cell Lung Cancer (NSCLC) Treatment<\/strong>.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\"><strong>Non-Small Cell Lung Cancer (NSCLC) key companies<\/strong> <\/span><span data-mce-mark=\"1\">involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Non-Small Cell Lung Cancer (NSCLC) Drugs<\/span><span data-mce-mark=\"1\"> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the <\/span><strong><span data-mce-mark=\"1\">Non-Small Cell Lung Cancer (NSCLC) market<\/span><\/strong><span data-mce-mark=\"1\">.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>The dynamics of the Non-small cell lung cancer (NSCLC) market is anticipated to change in the coming years owing to the improvement in the rise in healthcare spending across the world.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Non-Small Cell Lung Cancer (NSCLC) Companies:<\/strong><br \/>Sanofi<br \/>AbbVie<br \/>Roche<br \/>Merk<br \/>Novartis<br \/>Pfizer<br \/>AstraZeneca<br \/>GlaxoSmithKline<br \/>Bristol-Myers-Squibb<br \/>Takeda Pharmaceuticals<br \/>Johnson &amp; Johnson<br \/><strong>And many others.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Report Highlights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">A better understanding of disease pathogenesis contributing to the development of <\/span><strong><span data-mce-mark=\"1\">novel therapeutics for Non-Small Cell Lung Cancer (NSCLC)<\/span><\/strong><span data-mce-mark=\"1\">.&nbsp;&nbsp;&nbsp;&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">In the coming years, the <strong>Non-Small Cell Lung Cancer (NSCLC) market<\/strong> is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The companies and academics are working to assess challenges and seek opportunities that could influence <\/span><strong><span data-mce-mark=\"1\">Non-Small Cell Lung Cancer (NSCLC) Research &amp; Development<\/span><\/strong><span data-mce-mark=\"1\"><strong>.<\/strong> The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">A detailed portfolio of major pharma players who are involved in fueling the <\/span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong><span data-mce-mark=\"1\">Non-Small Cell Lung Cancer (NSCLC) treatment market<\/span><\/strong><\/a><span data-mce-mark=\"1\">. Several potential therapies for Non-Small Cell Lung Cancer (NSCLC) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Non-Small Cell Lung Cancer (NSCLC) market size in the coming years.&nbsp;&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Our in-depth analysis of the <\/span><strong><span data-mce-mark=\"1\">Non-Small Cell Lung Cancer (NSCLC) pipeline<\/span><\/strong><span data-mce-mark=\"1\"><strong> assets<\/strong> (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Table of Content<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">1. Report Introduction<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">2. Non-Small Cell Lung Cancer (NSCLC)&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">3. Non-Small Cell Lung Cancer (NSCLC) Current Treatment Patterns<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">4. Non-Small Cell Lung Cancer (NSCLC) &#8211; DelveInsight&#8217;s Analytical Perspective<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">5. Therapeutic Assessment<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">6. Non-Small Cell Lung Cancer (NSCLC) Late Stage Products (Phase-III)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">7. Non-Small Cell Lung Cancer (NSCLC) Mid Stage Products (Phase-II)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">8. Early Stage Products (Phase-I)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">9. Pre-clinical Products and Discovery Stage Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">10. Inactive Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">11. Dormant Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">12. Non-Small Cell Lung Cancer (NSCLC) Discontinued Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">13. Non-Small Cell Lung Cancer (NSCLC) Product Profiles<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">14. Non-Small Cell Lung Cancer (NSCLC) Key Companies<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">15. Non-Small Cell Lung Cancer (NSCLC) Key Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">16. Dormant and Discontinued Products<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">17. Non-Small Cell Lung Cancer (NSCLC) Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">18. Non-Small Cell Lung Cancer (NSCLC) Future Perspectives<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">19. Non-Small Cell Lung Cancer (NSCLC) Analyst Review&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">20. Appendix<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">21. Report Methodology<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Latest Reports By DelveInsight<\/strong><br \/><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\"><span data-mce-mark=\"1\"><strong>Non-Small Cell Lung Cancer (NSCLC) Market Insight<\/strong><br \/><\/span><\/a>DelveInsight&#8217;s &#8220;Non-Small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as Non-Small Cell Lung Cancer (NSCLC) market size, share, and trend analysis for the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan).<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/peripheral-vascular-devices-market-market\">Peripheral Vascular Devices Market<br \/><\/a><\/strong>DelveInsight&rsquo;s &lsquo;Peripheral Vascular Devices Market Insights, Competitive Landscape and Market Forecast &#8211; 2025&rsquo; report delivers an in-depth understanding of Peripheral Vascular Devices Market and the historical and forecasted Peripheral Vascular Devices market trends in the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><br \/>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=nonsmall-cell-lung-cancer-nsclc-pipeline-assessment-key-companies-and-emerging-drugs\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=nonsmall-cell-lung-cancer-nsclc-pipeline-assessment-key-companies-and-emerging-drugs\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP &#8220;Non-Small Cell Lung Cancer (NSCLC) Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Non-Small Cell Lung Cancer (NSCLC) Market. The Non-Small Cell Lung Cancer (NSCLC) &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/nonsmall-cell-lung-cancer-nsclc-pipeline-assessment-key-companies-and-emerging-drugs_540757.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-540757","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/540757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=540757"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/540757\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=540757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=540757"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=540757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}